Chondroitin sulfate in osteoarthritis of the knee: A prospective, double blind, placebo controlled multicenter clinical study

Journal of Rheumatology

Volumn 28, Issue 1, 2001, Pages 173-181

  Mazieres, B ^a   Combe, B ^a   Van, A P ^a   Tondut, J ^a   Grynfeltt, M ^a  

^a CHU RANGUEIL   (France)

Author keywords

Chondroitin sulfate; Clinical trial; Osteoarthritis; Slow acting drugs

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; CHONDROITIN SULFATE; DICLOFENAC; KETOPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; KNEE OSTEOARTHRITIS; MALE; MULTICENTER STUDY; OUTPATIENT; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADMINISTRATION, ORAL; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; CHONDROITIN SULFATES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS, KNEE; PAIN; PAIN MEASUREMENT; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0035161805     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Impact of joint impairment on longitudinal disability in elderly persons
2. The physical and psychological effect of moderate osteoarthritis of the knee
3. Physical and psychosocial disability in elderly subjects in relation to pain in the hip and/or knee
4. Costs, outcomes, and patient satisfaction by provider type for patients with rheumatic musculoskeletal conditions: A critical review of the literature and proposed methodologic standards
5. Les coûts socio-économiques de l'arthrose en France
6. The localization of osteoarthritis
7. Longitudinal radiological evaluation of osteoarthritis of the knee
8. Radiological progression of osteoarthritis: An 11-year follow-up study of the knee
9. The Bristol "OA500" study: Progression of osteoarthritis (OA) over 3 years and the relationship between clinical and radiographic changes at the knee joint
10. Validation study of a computerised version of the Western Ontario and McMaster Universities VA3.0 osteoarthritis index
11. Heterogeneity of articular cartilage
12. Regulation of normal and osteoarthritis chondrocyte IL-1 receptor
13. The interleukin-1 family: 10 years of discovery
14. Determination of cytokines in synovial fluids: Correlation with diagnosis and histomorphological characteristics of synovial tissue
15. Interactions between IL-1 and FGF on articular chondrocytes. Effects on cell growth, prostanoid production and receptor modulation
16. Temporal pattern of cysteine endopeptidase (cathepsin B) expression in cartilage and synovium from rabbit knees with experimental osteoarthritis: Gene expression in chondrocytes in response to interleukin-1 and matrix depletion
17. Interaction between human leukocyte elastase and chondroitin sulfate
18. Einige biochemische mechanismen der entzündungshemmenden aktivität von exogenem chondroitinsulfat
19. Effects of hyaluronic acid on the release of cartilage matrix proteoglycan and fibronectin from the cell matrix layer of chondrocyte cultures: Interactions between hyaluronic acid and chondroitin sulphate glycosaminoglycan
20. Study of 35 cases of arthritis treated with chondroitin sulphate
21. Retrospective study of 150 cases of arthritis and 85 cases of trauma treated with chondroitin sulphate
22. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee
23. Indexes of severity for osteoarthritis of the hip and knee
24. Measurement of pain
25. Radiological assessment of osteoarthritis
26. Score d'équivalence des anti-inflammatoires non stéroïdiens
27. Le chondroïtine sulfate dans le traitement de la gonarthrose et de la coxarthrose. Résultats à 5 mois d'une étude prospective multicentrique, controlée, en double aveugle, versus placebo
28. ANOVA, MANOVA my black hen: Comments on repeated measures
29. Analysis of ordinal categorical data
30. Design and conduct of clinical trials in patients with osteoarthritis: Preliminary recommendations from a task force osteoarthritis research society
31. Factors associated with osteoarthritis of the knee in the first national Health and Nutrition Examination Survey (HANES I); evidence for an association with overweight, race, and physical demands of work
32. Social support, stress and functional status in patients with osteoarthritis
33. The application of the principle of intention-to-treat to the analysis of clinical trials
34. Clinical trial with chondroitin sulfate in gonarthrosis
35. Double-blind, dose effect study of oral chondroitin 4&6 sulfate 1200 mg, 800 mg, 200 mg and placebo in the treatment of knee osteoarthritis
36. Cytokines, prostaglandines E, phospholipase A2 et métalloprotéases du liquide synovial dans l'arthrose
37. Efficacy and tolerability of 800 mg oral chondroitin 4&6 sulfate in the treatment of knee osteoarthritis: A randomized, double-blind, multicentre study versus placebo
38. Glucosamine sulfate in gonarthrosis: Efficacy in placebo controlled studies
39. Diacerhein in the treatment of osteoarthritis of the hip
40. Italian double-blind multicenter study comparing S-adenosylmethionine, naproxen, and placebo in the treatment of degenerative joint disease
41. Osteoarthritis treatment update: Minimizing pain while limiting patient risk
42. Osteoarthritis
43. Approche de l'intensité de l'effet placebo dans l'évaluation des anti-arthrosiques symptomatiques d'action lente
44. Klinidche doppelblind-studie mit oral verabreichtem chondroitinsulfat gegen placebo bei der tibiofemoralen gonarthrose (125 patienten)
45. Efficacy and safety of avocado/soybean unsaponifiables in the treatment of symptomatic osteoarthritis of the knee and hip. A prospective, multicenter, three-month, randomized, double-blind, placebo-controlled trial
46. Méthodologie des essais cliniques des traitements de fond de l'arthrose
47. Validation study of WOMAC: A health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee